NCT04077099 - A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

231

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

March 9, 2032

Study Completion Date

March 9, 2032

Conditions

NSCLC

Interventions

DRUG

REGN5093

Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.

Trial Locations (30)

10016

Regeneron Research Facility, New York

10029

Regeneron Research Facility, New York

10065

Regeneron Research Facility, New York

10408

Regeneron Research Facility, Gyeonggi-do

14076

Regeneron Study Site, Caen

15232

Regeneron Research Facility, Pittsburgh

16247

Regeneron Research Facility, Suwon

19111

Regeneron Research Facility, Philadelphia

20007

Regeneron Research Facility, Washington D.C.

21034

Regeneron Research Facility, Dijon

27710

Regeneron Research Facility, Durham

33076

Regeneron Research Facility, Bordeaux

33612

Regeneron Research Facility, Tampa

34295

Regeneron Research Facility, Montpellier

35033

Regeneron Research Facility, Rennes

35294

Regeneron Research Facility, Birmingham

38043

Regeneron Research Facility, Grenoble

40536

Regeneron Research Facility, Lexington

48202

Regeneron Research Facility, Detroit

63110

Regeneron Research Facility, St Louis

73104

Regeneron Research Facility, Oklahoma City

75390

Regeneron Research Facility, Dallas

77030

Regeneron Research Facility, Houston

92868

Regeneron Research Facility, Orange